الملخص
Endometrial cancer (EC) is the most common gynaecological cancer. The combination of lenvatinib and pembrolizumab has exhibited efficacy as the second line treatment for advanced EC, with a significant benefit in terms of progression free survival (PFS) and overall survival, but the adverse events (AE) profile is complex. AEs associated with the treatment may represent a limitation to this combination. Here, we report the case of a 38-year-old female patient diagnosed with stage IV EC elsewhere, whose disease progressed after the first line of treatment and was referred to a specialised cacncer centre in Muscat, Oman, in 2021. We treated her with the combination of lenvatinib and pembrolizumab. During the course of the treatment, she developed hand-foot syndrome grade III and hypothyroidism grade II. The AEs were managed with supportive medications, dose interruptions, dose reductions and multidisciplinary care, which allowed the continuation of the treatment. The patient achieved a good partial response and an ongoing PFS of more than 12 months. Keywords: Cancer; Endometrial Cancer; Lenvatinib; Pembrolizumab; Adverse Drug Events; Hand-Foot Syndrome; Hypothyroidism; Oman.
بيانات النشر
- المعرّف الرقمي
- 10.18295/squmj.9.2023.057
- المجلة
- مجلة جامعة السلطان قابوس الطبية, 24(2), 293-297
- الناشر
- جامعة السلطان قابوس
- وصول مفتوح
- وصول مفتوح ذهبي
- الترخيص
- CC BY-ND 4.0
اقتبس هذه المقالة
APA 7
Zribi, A., Al Riyami, K., Al Zahibi, H. S., & Burney, I. A. (2025). Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer. Sultan Qaboos University Medical Journal, 24(2), 293-297. https://doi.org/10.18295/squmj.9.2023.057
MLA 9
Zribi, Aref, et al. "Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer." Sultan Qaboos University Medical Journal, vol. 24, no. 2, 2025, pp. 293-297. https://doi.org/10.18295/squmj.9.2023.057.
شيكاغو (المؤلف–التاريخ)
Zribi, Aref, Khulood Al Riyami, Hajar S. Al Zahibi, and Ikram A. Burney. 2025. "Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer." Sultan Qaboos University Medical Journal 24 (2): 293-297. https://doi.org/10.18295/squmj.9.2023.057.
هارفارد
Zribi, A., Al Riyami, K., Al Zahibi, H. S. and Burney, I. A. (2025) 'Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer', Sultan Qaboos University Medical Journal, 24(2), pp. 293-297. doi:10.18295/squmj.9.2023.057.
فانكوفر
Zribi A, Al Riyami K, Al Zahibi HS, Burney IA. Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer. Sultan Qaboos University Medical Journal. 2025;24(2):293-297. doi:10.18295/squmj.9.2023.057
IEEE
A. Zribi, K. Al Riyami, H. S. Al Zahibi, and I. A. Burney, "Managing the Adverse Events Associated with Pembrolizumab and Lenvatinib Therapy in Endometrial Cancer," Sultan Qaboos University Medical Journal, vol. 24, no. 2, pp. 293-297, 2025, doi: 10.18295/squmj.9.2023.057.